Driehaus Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Driehaus Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-8,056	Closed	-$848K	–	552
2015 Q3	$848K	Buy	+8,056	New	+$1.08M	0.03%	365
2015 Q1	–	Sell	-14,078	Closed	-$1.27M	–	500
2014 Q4	$1.27M	Sell	14,078 -10,446	-43%	-$869K	0.05%	374
2014 Q3	$1.77M	Buy	+24,524	New	+$1.61M	0.07%	348
2014 Q2	–	Sell	-25,018	Closed	-$1.71M	–	561
2014 Q1	$1.71M	Sell	25,018 -110,718	-82%	-$8.16M	0.05%	353
2013 Q4	$9.54M	Buy	135,736 +29,843	+28%	+$2.03M	0.34%	79
2013 Q3	$7.65M	Sell	105,893 -94,047	-47%	-$6.25M	0.3%	110
2013 Q2	$11.2M	Buy	+199,940	New	+$12.5M	0.49%	42

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Driehaus Capital Management's BMRN Position: Q4 2015 in Review

Driehaus Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 8,056 shares — an estimated $848K sold.

Driehaus Capital Management first reported a position in BMRN in Q2 2013 and held it in 7 quarters. The position peaked at $11.2M in Q2 2013. 389 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

Driehaus Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Driehaus Capital Management sold 8,056 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $848K.
Driehaus Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Driehaus Capital Management's BioMarin Pharmaceuticals position peaked at $11.2M in Q2 2013.
389 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Driehaus Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.